Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6955815 | 0.84 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4AHRLMNA | |
| SCHEMBL10990350 | 0.82 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL18386352 | 0.81 | L3MBTL1 (0.46) | ATML3MBTL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8332289 | 0.79 | HPGD (0.39) | ATML3MBTL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30021683 | 0.77 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL10667194 | 0.76 | SLC6A2 (0.38) | SLC6A3SLC6A2SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL17109517 | 0.75 | ESR2 (0.38) | ATML3MBTL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6122435 | 0.75 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4AHRLMNA | |
| SCHEMBL5879335 | 0.74 | ESR1 (0.37) | ATML3MBTL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11149256 | 0.74 | ESR1 (0.58) | SLC6A3SLC6A2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034056-B2 | Aryl and biaryl compounds having MCH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-0994876-B1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
| EP-1370520-A1 | ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-0790248-B1 | 3-Aza-piperidone- (tetrahydropyrimidin-2-one) and 3-oxa-piperidone (1,3 oxazin-2-one) derivatives, their preparation and their use as tachykinin/neurokinin antagonists | PFIZER LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| EP-0791592-B1 | Azetidines | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
| EP-0871623-B1 | 3-AZETIDINYLALKYLPIPERIDINES OR -PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER RES & DEV (IE) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002076929-A1 | ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0888337-B1 | PIPERIDONE TACHYKININ ANTAGONISTS | PFIZER RES & DEV (IE) | 2002-06-05 | — | — | EP | disclosed |
| US-6380396-B1 | CHEMICAL INTERMEDIATES FOR ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| US-6022971-A | Azetidines | PFIZER INC (US) | 2000-02-08 | — | — | US | disclosed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5846965-A | 3-aza and 3-oxa piperidone tachykinin antagonists | PFIZER INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0871623-A1 | 3-AZETIDINYLALKYLPIPERIDINES OR -PYRROLIDINES AS TACHYKININ ANTAGONISTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | disclosed |
| US-5741790-A | Azetidines | PFIZER INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0797576-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | disclosed |
| EP-0790248-A1 | 3-Aza-piperidone- (tetrahydropyrimidin-2-one) and 3-oxa-piperidone (1,3 oxazin-2-one) derivatives, their preparation and their use as tachykinin/neurokinin antagonists | Pfizer Limited (GB) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997025322-A1 | 3-AZETIDINYLALKYLPIPERIDINES OR -PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-17 | — | — | WO | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | MCHR1, MCHR2, MC3R | SLC6A3 889/4885SLC6A2 641/4885SLC6A4 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.